CapsoVision (CV) Competitors

CapsoVision logo
$6.94 -0.05 (-0.72%)
As of 02:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CV vs. ENOV, BLFS, KMTS, PRCT, and INSP

Should you buy CapsoVision stock or one of its competitors? MarketBeat compares CapsoVision with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CapsoVision include Enovis (ENOV), BioLife Solutions (BLFS), Kestra Medical Technologies (KMTS), PROCEPT BioRobotics (PRCT), and Inspire Medical Systems (INSP). These companies are all part of the "medical equipment" industry.

How does CapsoVision compare to Enovis?

Enovis (NYSE:ENOV) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

98.5% of Enovis shares are held by institutional investors. 2.9% of Enovis shares are held by company insiders. Comparatively, 2.3% of CapsoVision shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Enovis has a net margin of -49.92% compared to CapsoVision's net margin of -198.87%. Enovis' return on equity of 10.32% beat CapsoVision's return on equity.

Company Net Margins Return on Equity Return on Assets
Enovis-49.92% 10.32% 4.57%
CapsoVision -198.87%N/A -136.03%

CapsoVision has lower revenue, but higher earnings than Enovis. CapsoVision is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enovis$2.25B0.56-$1.18B-$19.88N/A
CapsoVision$13.56M25.57-$25.32M-$2.34N/A

Enovis presently has a consensus target price of $44.50, suggesting a potential upside of 102.41%. CapsoVision has a consensus target price of $8.50, suggesting a potential upside of 22.48%. Given Enovis' stronger consensus rating and higher possible upside, equities analysts clearly believe Enovis is more favorable than CapsoVision.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enovis
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
CapsoVision
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

In the previous week, Enovis and Enovis both had 2 articles in the media. CapsoVision's average media sentiment score of 0.93 beat Enovis' score of 0.00 indicating that CapsoVision is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Enovis
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
CapsoVision
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Enovis beats CapsoVision on 10 of the 15 factors compared between the two stocks.

How does CapsoVision compare to BioLife Solutions?

CapsoVision (NASDAQ:CV) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

CapsoVision presently has a consensus price target of $8.50, indicating a potential upside of 22.48%. BioLife Solutions has a consensus price target of $32.00, indicating a potential upside of 14.02%. Given CapsoVision's stronger consensus rating and higher possible upside, equities analysts clearly believe CapsoVision is more favorable than BioLife Solutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CapsoVision
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50
BioLife Solutions
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

BioLife Solutions has a net margin of -2.80% compared to CapsoVision's net margin of -198.87%. BioLife Solutions' return on equity of 1.81% beat CapsoVision's return on equity.

Company Net Margins Return on Equity Return on Assets
CapsoVision-198.87% N/A -136.03%
BioLife Solutions -2.80%1.81%1.65%

BioLife Solutions has higher revenue and earnings than CapsoVision. BioLife Solutions is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CapsoVision$13.56M25.57-$25.32M-$2.34N/A
BioLife Solutions$96.21M14.25-$4.59M-$0.08N/A

In the previous week, CapsoVision had 1 more articles in the media than BioLife Solutions. MarketBeat recorded 2 mentions for CapsoVision and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.90 beat CapsoVision's score of 0.93 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company Overall Sentiment
CapsoVision Positive
BioLife Solutions Very Positive

93.2% of BioLife Solutions shares are owned by institutional investors. 2.3% of CapsoVision shares are owned by company insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

BioLife Solutions beats CapsoVision on 9 of the 16 factors compared between the two stocks.

How does CapsoVision compare to Kestra Medical Technologies?

Kestra Medical Technologies (NASDAQ:KMTS) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Kestra Medical Technologies has a net margin of -171.87% compared to CapsoVision's net margin of -198.87%. CapsoVision's return on equity of 0.00% beat Kestra Medical Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Kestra Medical Technologies-171.87% -65.49% -46.39%
CapsoVision -198.87%N/A -136.03%

In the previous week, Kestra Medical Technologies had 2 more articles in the media than CapsoVision. MarketBeat recorded 4 mentions for Kestra Medical Technologies and 2 mentions for CapsoVision. CapsoVision's average media sentiment score of 0.93 beat Kestra Medical Technologies' score of 0.47 indicating that CapsoVision is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kestra Medical Technologies
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
CapsoVision
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

CapsoVision has lower revenue, but higher earnings than Kestra Medical Technologies. Kestra Medical Technologies is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kestra Medical Technologies$59.81M23.44-$113.81M-$3.96N/A
CapsoVision$13.56M25.57-$25.32M-$2.34N/A

Kestra Medical Technologies presently has a consensus price target of $27.40, suggesting a potential upside of 14.10%. CapsoVision has a consensus price target of $8.50, suggesting a potential upside of 22.48%. Given CapsoVision's stronger consensus rating and higher possible upside, analysts clearly believe CapsoVision is more favorable than Kestra Medical Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kestra Medical Technologies
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
CapsoVision
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

Summary

CapsoVision beats Kestra Medical Technologies on 9 of the 14 factors compared between the two stocks.

How does CapsoVision compare to PROCEPT BioRobotics?

PROCEPT BioRobotics (NASDAQ:PRCT) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

89.5% of PROCEPT BioRobotics shares are held by institutional investors. 6.6% of PROCEPT BioRobotics shares are held by company insiders. Comparatively, 2.3% of CapsoVision shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

PROCEPT BioRobotics has a net margin of -31.82% compared to CapsoVision's net margin of -198.87%. CapsoVision's return on equity of 0.00% beat PROCEPT BioRobotics' return on equity.

Company Net Margins Return on Equity Return on Assets
PROCEPT BioRobotics-31.82% -27.70% -20.29%
CapsoVision -198.87%N/A -136.03%

CapsoVision has lower revenue, but higher earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than CapsoVision, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PROCEPT BioRobotics$308.05M4.06-$95.57M-$1.82N/A
CapsoVision$13.56M25.57-$25.32M-$2.34N/A

In the previous week, PROCEPT BioRobotics had 1 more articles in the media than CapsoVision. MarketBeat recorded 3 mentions for PROCEPT BioRobotics and 2 mentions for CapsoVision. PROCEPT BioRobotics' average media sentiment score of 1.70 beat CapsoVision's score of 0.93 indicating that PROCEPT BioRobotics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PROCEPT BioRobotics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
CapsoVision
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

PROCEPT BioRobotics currently has a consensus price target of $40.42, indicating a potential upside of 84.15%. CapsoVision has a consensus price target of $8.50, indicating a potential upside of 22.48%. Given PROCEPT BioRobotics' higher probable upside, research analysts clearly believe PROCEPT BioRobotics is more favorable than CapsoVision.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PROCEPT BioRobotics
2 Sell rating(s)
5 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.47
CapsoVision
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

Summary

PROCEPT BioRobotics beats CapsoVision on 10 of the 15 factors compared between the two stocks.

How does CapsoVision compare to Inspire Medical Systems?

CapsoVision (NASDAQ:CV) and Inspire Medical Systems (NYSE:INSP) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

94.9% of Inspire Medical Systems shares are held by institutional investors. 2.3% of CapsoVision shares are held by insiders. Comparatively, 2.2% of Inspire Medical Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Inspire Medical Systems has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CapsoVision$13.56M25.57-$25.32M-$2.34N/A
Inspire Medical Systems$915.25M1.40$145.42M$4.499.94

In the previous week, CapsoVision and CapsoVision both had 2 articles in the media. CapsoVision's average media sentiment score of 0.93 beat Inspire Medical Systems' score of -0.67 indicating that CapsoVision is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CapsoVision
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Inspire Medical Systems
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative

CapsoVision presently has a consensus target price of $8.50, suggesting a potential upside of 22.48%. Inspire Medical Systems has a consensus target price of $81.05, suggesting a potential upside of 81.63%. Given Inspire Medical Systems' higher possible upside, analysts plainly believe Inspire Medical Systems is more favorable than CapsoVision.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CapsoVision
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50
Inspire Medical Systems
3 Sell rating(s)
13 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.05

Inspire Medical Systems has a net margin of 14.33% compared to CapsoVision's net margin of -198.87%. Inspire Medical Systems' return on equity of 10.35% beat CapsoVision's return on equity.

Company Net Margins Return on Equity Return on Assets
CapsoVision-198.87% N/A -136.03%
Inspire Medical Systems 14.33%10.35%8.81%

Summary

Inspire Medical Systems beats CapsoVision on 10 of the 15 factors compared between the two stocks.

Get CapsoVision News Delivered to You Automatically

Sign up to receive the latest news and ratings for CV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CV vs. The Competition

MetricCapsoVisionSurgical, Medical, And Dental Instruments And Supplies IndustryManufacturing SectorNASDAQ Exchange
Market Cap$344.00M$2.91B$4.36B$12.22B
Dividend YieldN/AN/A11.51%5.90%
P/E Ratio-2.9414.4522.0124.07
Price / Sales25.57346.67203.1699.97
Price / CashN/A8.0938.0153.91
Price / Book24.795.8913.216.33
Net Income-$25.32M$7.39M$115.37M$337.69M
7 Day Performance4.99%-4.94%-1.33%-0.71%
1 Month Performance4.83%-9.85%-2.68%-0.10%
1 Year PerformanceN/A2.73%11.32%26.23%

CapsoVision Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CV
CapsoVision
1.0166 of 5 stars
$6.94
-0.7%
$8.50
+22.5%
N/A$344.00M$13.56MN/A90
ENOV
Enovis
3.7697 of 5 stars
$21.34
-2.9%
$44.50
+108.5%
-31.9%$1.23B$2.25BN/A7,802
BLFS
BioLife Solutions
3.3106 of 5 stars
$24.90
-4.4%
$32.00
+28.5%
+28.7%$1.22B$96.21MN/A440
KMTS
Kestra Medical Technologies
1.6545 of 5 stars
$20.73
+4.0%
$27.40
+32.2%
+27.7%$1.21B$59.81MN/A300
PRCT
PROCEPT BioRobotics
3.2179 of 5 stars
$21.06
-3.0%
$41.36
+96.4%
-63.1%$1.20B$308.05MN/A430

Related Companies and Tools


This page (NASDAQ:CV) was last updated on 6/26/2026 by MarketBeat.com Staff.
From Our Partners